Despite the proven benefits of hormone therapy and its addition of estrogen into the human body, it carries with it certain side effects. The most notorious of these is the increased risk of contracting breast cancer that has been consistently associated with undergoing hormone therapy. Clinical testing of estrogens effect in this regard has shown that its infusion into the body through hormone therapy can increase the risks of breast cancer in certain groups of women. Such studies showed that this was of particular relevance to women who were leaner or for those who had tumors which were not very clinically advanced. A more recent study has monitored further women who were in previous years tested for breast cancer in relation to their hormone therapy.
As a powerful chemical to place into the body's natural hormonal balance, estrogen can cause a number of side effects. The possible onset of breast cancer has been noted as one of these potential side effects. Studies have shown that such prevalence is sometimes dependant on the presence of a tumor, or the body mass of the woman. Such studies have also shown that the type of estrogen program is also directly linked to the risk of breast cancer. Clinical trials found that a combined program of estrogen, such as estrogen-progestin carry with it a greater risk of increasing the chances of developing breast cancer then through taking estrogen alone. The study also found that such results in the comparison of the risks between estrogen and estrogen-progestin treatment are complicated by other elements. The main factor is the body mass of the women tested. For estrogen alone the risk increased in lean women but not for heavy women monitored in the study. Further analysis has then shown that there's a definite risk for women who decide to use hormone therapy in order to treat their menopausal symptoms.
Such tests have further concluded what initial testing in this regard had already begun to show. The link between artificial estrogen into the body through hormone therapy is a valid option for many women experiencing the symptoms of menopause, but such treatment brings with it certain risks. Such risks have been show to have a great deal more efficacy depending on a number of variables. The increase risk of breast cancer can be identified more so for estrogen -proestrogen in lean women but less so in women with more body mass. The use of such therapy should be carefully considered and any final decisions should only be made when all of these variables have been taken into account.
